Moderna, Merck mRNA vaccine cuts melanoma recurrence risk by 42%

A wide-scale clinical study has revealed that an experimental personalized vaccine lowered the risk of skin cancer recurrence by 42%. The treatment was administered alongside standard immunotherapy following surgery for high-risk melanoma. This development strengthens hopes for limiting disease relapse.

Pharmaceutical companies Moderna and Merck announced the results, which involved more than 1,100 patients with high-risk melanoma who had their tumors surgically removed. The vaccine, known as Intismeran, relies on messenger RNA (mRNA) technology, the same platform used to develop COVID-19 vaccines.

Mechanism of Personalized Vaccine

Unlike traditional vaccines that prevent infection, this formulation is designed to help the immune system detect and attack cancer cells if they return after surgery. The process begins with analyzing the tumor's genetic characteristics to identify mutations that distinguish it. These mutations may lead to the production of unfamiliar proteins known as neoantigens.

A custom vaccine is then manufactured for each patient to train their immune system to recognize these markers and target cells carrying them. The regimen includes nine doses spaced three weeks apart, given concurrently with Keytruda, an immunotherapy drug produced by Merck. This strategy differs from preventive vaccines such as those for human papillomavirus or hepatitis B, which help prevent certain infection-related cancers.

Clinical Trial Outcomes

Participants were randomly assigned to two groups: one received the personalized vaccine plus Keytruda, while the other received immunotherapy with a placebo. After two years, 82% of patients who received the vaccine remained alive without cancer recurrence, compared to 70% of those who received immunotherapy alone. This represents a 12 percentage point difference.

The 42% reduction in recurrence risk refers to the relative decrease in hazard according to study results, not a 42 percentage point increase in cure rates. The trial continues to monitor participants and assess long-term outcomes.

Patient Experience and Side Effects

Tony Hout, 62, joined the trial in 2024 at MD Anderson Cancer Center after discovering a bleeding spot on his ear that would not heal. Doctors confirmed his melanoma diagnosis, and surgery revealed the disease had begun to spread. Hout stated he wants to do everything possible to stay with his family, noting he travels from Indiana to Houston every few months for tests.

Recent examinations showed Hout remains cancer-free, although his individual case alone is insufficient to judge the therapy's effectiveness. According to researcher Dr. Hussein Tawbi, main side effects included injection site pain, fatigue, and reactions similar to those associated with approved mRNA-based coronavirus vaccines.

Production Costs and Future Expansion

Moderna and Merck have not disclosed expected costs for the vaccine, amid concerns about high prices for personalized treatments requiring genetic analysis and custom manufacturing for each patient. Steven Hogue, head of Moderna, said the company’s Massachusetts facility produces doses for thousands of participants in international studies. Manufacturing the vaccine takes a few days, while the entire process, starting from tumor analysis, may take six weeks or more. During this period, patients begin standard treatment with Keytruda.

Experts believe the study's success enhances prospects for developing personalized vaccines for other types of cancer, as research is underway on similar treatments targeting lung, kidney, and pancreatic cancers. Karen Nudsen, CEO of the Parker Institute, described the technology as a new frontier in research, while Dr. Michael Atkins from Georgetown University noted its potential future application to multiple cancers.

The companies are currently discussing necessary steps for regulatory approval with authorities. However, the vaccine remains experimental and requires long-term follow-up to evaluate the sustainability of its efficacy and safety.